drugset / Trial / NCT05886257
Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T
NaSingle-groupOpen-labelTreatment
Summary
To explore the efficacy and safety of candonilimab plus bevacizumab for patients with advanced hepatocellular carcinoma who progressed on atezolizumab plus bevacizumab.
Timeline
- Start
- 2022-12-07
- Primary completion
- 2023-03-31
- Completion
- 2023-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Candonilimab | Monoclonal antibody | 10 mg/kg | Intravenous |